DDInter259 DDInter1676
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Cabazitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Cabazitaxel {u} (Compound) treats {v} (Disease) prostate cancer
Cabazitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Cabazitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Cabazitaxel {u} (Compound) causes {v} (Side Effect) Cardiac failure
Cabazitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cabazitaxel (Compound) resembles Docetaxel (Compound)
Cabazitaxel (Compound) treats prostate cancer (Disease)
Cabazitaxel (Compound) binds CYP3A5 (Gene)
Cabazitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Cabazitaxel (Compound) causes Cardiac failure (Side Effect)
Cabazitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Cabazitaxel may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel may lead to a major life threatening interaction when taken with Clozapine